Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD: Milestones in Drug Therapy
Editat de Alexandre Trifilieffen Limba Engleză Hardback – 27 noi 2013
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Din seria Milestones in Drug Therapy
- 5% Preț: 1335.08 lei
- 5% Preț: 840.04 lei
- 5% Preț: 352.33 lei
- 5% Preț: 346.30 lei
- 5% Preț: 673.98 lei
- 5% Preț: 683.20 lei
- 5% Preț: 614.47 lei
- 5% Preț: 1044.69 lei
- 5% Preț: 1332.81 lei
- 5% Preț: 345.42 lei
- 5% Preț: 667.35 lei
- 5% Preț: 1035.69 lei
- 5% Preț: 342.13 lei
- 5% Preț: 671.21 lei
- 5% Preț: 345.96 lei
- 5% Preț: 1041.22 lei
- 5% Preț: 1038.44 lei
- 5% Preț: 1216.12 lei
- 5% Preț: 607.64 lei
- 5% Preț: 1042.44 lei
- 5% Preț: 1521.72 lei
- 5% Preț: 1350.30 lei
- 5% Preț: 671.69 lei
- 5% Preț: 672.77 lei
- 5% Preț: 1706.11 lei
- 5% Preț: 1042.10 lei
- 5% Preț: 1340.73 lei
- 5% Preț: 1034.82 lei
- 5% Preț: 678.83 lei
- 5% Preț: 680.41 lei
- 5% Preț: 1027.37 lei
- 5% Preț: 1033.75 lei
- 5% Preț: 1035.20 lei
- 5% Preț: 1045.04 lei
- 5% Preț: 1217.84 lei
Preț: 677.61 lei
Preț vechi: 713.28 lei
-5% Nou
Puncte Express: 1016
Preț estimativ în valută:
129.70€ • 139.46$ • 108.13£
129.70€ • 139.46$ • 108.13£
Carte tipărită la comandă
Livrare economică 19 decembrie 24 - 02 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783034807081
ISBN-10: 3034807082
Pagini: 156
Ilustrații: VII, 146 p. 41 illus., 21 illus. in color.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.41 kg
Ediția:2014
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy
Locul publicării:Basel, Switzerland
ISBN-10: 3034807082
Pagini: 156
Ilustrații: VII, 146 p. 41 illus., 21 illus. in color.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.41 kg
Ediția:2014
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy
Locul publicării:Basel, Switzerland
Public țintă
ResearchCuprins
Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?
Textul de pe ultima copertă
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Caracteristici
Summarizes preclinical and clinical data A valuable source of information for scientists and clinicians Contemporary monograph on the pharmacotherapy of COPD Includes supplementary material: sn.pub/extras